MARKET NEWS

OSE Immunotherapeutics & Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial
BrainStorm Cell Therapeutics Announces Submission of IND
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Clinical Trial
Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials
New Phase 1 Zika Vaccine Trial Meets Primary Endpoint
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA

  FEATURED EDITORIAL

  COMPANY PROFILE

Drug Delivery Experts (DDE Labs) is a contract R&D drug delivery laboratory located in San Diego’s emerging biotech sector that specializes in drug product development. We have the expertise to integrate drug delivery formulations with the appropriate device to maximize commercial potential. DDE Labs was created in 2014 to address the gap of good outsourcing partners in the formulation and drug delivery technology landscape. We specialize in drug-device combination product development and integration of formulation and delivery system approaches with commercial strategy and life-cycle plans. We work in the injectable products space as well as alternate delivery systems. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cambrex to Acquire Avista Pharma Solutions

Cambrex to Acquire Avista Pharma Solutions

Cambrex Corporation recently announced it has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.

Roivant Sciences & iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic; Deal Worth 7.5 Milllion

Roivant Sciences & iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic; Deal Worth $667.5 Milllion

Roivant Sciences and iNtRON Biotechnology recently announced they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of $667.5 million inclusive of milestone payments, with royalties on net sales in the low double digits.

CordenPharma Announces Successful SafeBridge Recertification

CordenPharma Announces Successful SafeBridge Recertification

CordenPharma Colorado has successfully completed the Potent Compound Recertification Audit by SafeBridge Consultants. Certification has been maintained since first awarded in 2013.

Catalent to Open Second Clinical Supply Facility; Enables Broader Integrated Solutions for Global & Local Customers

Catalent to Open Second Clinical Supply Facility; Enables Broader Integrated Solutions for Global & Local Customers

Catalent Pharma Solutions recently announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the facility is expected to employ 100 people and will double Catalent’s total clinical storage capacity in China.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 5 – Capsules
December 12 – Controlled Release